HK1207077A1 - -二氟-芐基 -吲唑- -基 -甲基-哌嗪- -基 四氫-吡喃- -基氨基 -苯甲酰胺的製備方法 - Google Patents
-二氟-芐基 -吲唑- -基 -甲基-哌嗪- -基 四氫-吡喃- -基氨基 -苯甲酰胺的製備方法Info
- Publication number
- HK1207077A1 HK1207077A1 HK15107770.4A HK15107770A HK1207077A1 HK 1207077 A1 HK1207077 A1 HK 1207077A1 HK 15107770 A HK15107770 A HK 15107770A HK 1207077 A1 HK1207077 A1 HK 1207077A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- indazol
- ylamino
- benzamide
- pyran
- difluoro
- Prior art date
Links
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12169139 | 2012-05-23 | ||
PCT/EP2013/060534 WO2013174876A1 (en) | 2012-05-23 | 2013-05-22 | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207077A1 true HK1207077A1 (zh) | 2016-01-22 |
Family
ID=48470987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107770.4A HK1207077A1 (zh) | 2012-05-23 | 2015-08-11 | -二氟-芐基 -吲唑- -基 -甲基-哌嗪- -基 四氫-吡喃- -基氨基 -苯甲酰胺的製備方法 |
Country Status (18)
Country | Link |
---|---|
US (3) | US9085565B2 (zh) |
EP (4) | EP3581571A1 (zh) |
JP (1) | JP6231556B2 (zh) |
KR (1) | KR102151963B1 (zh) |
CN (2) | CN104395308B (zh) |
AR (1) | AR091138A1 (zh) |
AU (2) | AU2013265288B2 (zh) |
BR (1) | BR112014028841B1 (zh) |
CA (1) | CA2873979C (zh) |
ES (2) | ES2751944T3 (zh) |
HK (1) | HK1207077A1 (zh) |
IL (2) | IL235761B (zh) |
MX (1) | MX355409B (zh) |
NZ (2) | NZ716487A (zh) |
PL (2) | PL3333166T3 (zh) |
RU (1) | RU2602071C2 (zh) |
TW (1) | TWI579280B (zh) |
WO (1) | WO2013174876A1 (zh) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5506674B2 (ja) * | 2007-07-20 | 2014-05-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性な置換インダゾール誘導体 |
PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
ES2900243T3 (es) | 2008-10-22 | 2022-03-16 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
MX2012013467A (es) | 2010-05-20 | 2013-04-29 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de trk cinasa. |
RU2602071C2 (ru) | 2012-05-23 | 2016-11-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида |
WO2015017533A1 (en) | 2013-07-30 | 2015-02-05 | Blueprint Medicines Corporation | Ntrk2 fusions |
TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ros1突變癌細胞之分子 |
EP3699181B1 (en) | 2014-11-16 | 2023-03-01 | Array Biopharma, Inc. | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
CA2969540C (en) | 2014-12-02 | 2023-03-21 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
US20170356918A1 (en) * | 2014-12-03 | 2017-12-14 | Ignyta, Inc. | Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer |
MA41667A1 (fr) | 2015-06-01 | 2018-08-31 | Loxo Oncology Inc | Procede de diagnostic et de traitement du cancer |
CA2992586A1 (en) | 2015-07-16 | 2017-01-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
US10724102B2 (en) | 2015-10-26 | 2020-07-28 | Loxo Oncology, Inc. | Point mutations in TRK inhibitor-resistant cancer and methods relating to the same |
WO2017106492A1 (en) | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinations for the treatment of cancer |
CA3019671C (en) | 2016-04-04 | 2024-02-20 | Loxo Oncology, Inc. | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
KR20180129911A (ko) | 2016-04-04 | 2018-12-05 | 록쏘 온콜로지, 인코포레이티드 | 소아암을 치료하는 방법 |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
PL3458456T3 (pl) | 2016-05-18 | 2021-04-19 | Loxo Oncology, Inc. | Wytwarzanie (s)-n-(5-((r)-2-(2,5-difluorofenylo)pirolidyn-1-ylo)pirazolo [1,5-a]pirymidyn-3-ylo)-3-hydroksypirolidyno-1-karbokysamidu |
ES2899953T3 (es) | 2016-05-24 | 2022-03-15 | Nerviano Medical Sciences Srl | Nueva forma cristalina de n-[5-(3,5-difluoro-bencil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetrahidro-piran-4-ilamino)-benzamida |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
WO2018130928A1 (en) * | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
JP7203083B2 (ja) | 2017-07-19 | 2023-01-12 | イグナイタ インコーポレイテッド | エントレクチニブを含む薬学的組成物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
CN111225662B (zh) | 2017-10-17 | 2022-11-22 | 伊尼塔公司 | 药物组合物和剂型 |
US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物 |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
EP3849986B1 (en) | 2018-09-10 | 2022-06-08 | Array Biopharma, Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
AU2020319662B2 (en) * | 2019-07-31 | 2024-02-29 | F. Hoffmann-La Roche Ag | New pharmaceutical formulation |
US20220372024A1 (en) * | 2019-11-01 | 2022-11-24 | Johnson Matthey Public Limited Company | Crystalline forms of entrectinib |
CN113024521B (zh) * | 2019-12-09 | 2023-01-17 | 武汉九州钰民医药科技有限公司 | 一种制备恩曲替尼的方法 |
CN111171009B (zh) * | 2020-01-10 | 2022-07-12 | 安礼特(上海)医药科技有限公司 | 恩曲替尼晶型及其制备方法 |
CN113801062B (zh) * | 2020-06-15 | 2023-05-26 | 沈阳药科大学 | 3-氨基-5-(3,5-二氟苄基)-1h-吲唑的制备方法 |
EP4273144A1 (en) | 2021-02-03 | 2023-11-08 | Qilu Pharmaceutical Co., Ltd. | Crystal form of entrectinib and preparation method therefor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI58125C (fi) * | 1976-12-15 | 1985-01-02 | Orion Yhtymae Oy | Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolin med blodtryckssaenkande vekan |
DE19730989A1 (de) * | 1997-07-18 | 1999-01-21 | Merck Patent Gmbh | Piperazin-Derivate |
ES2509820T3 (es) * | 2006-12-20 | 2014-10-20 | Nerviano Medical Sciences S.R.L. | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer |
JP5506674B2 (ja) * | 2007-07-20 | 2014-05-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性な置換インダゾール誘導体 |
JP5580332B2 (ja) * | 2008-12-18 | 2014-08-27 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性な置換インダゾール誘導体 |
RU2602071C2 (ru) | 2012-05-23 | 2016-11-10 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида |
-
2013
- 2013-05-22 RU RU2014151565/04A patent/RU2602071C2/ru active
- 2013-05-22 ES ES17192138T patent/ES2751944T3/es active Active
- 2013-05-22 BR BR112014028841-0A patent/BR112014028841B1/pt active IP Right Grant
- 2013-05-22 JP JP2015513159A patent/JP6231556B2/ja active Active
- 2013-05-22 TW TW102118026A patent/TWI579280B/zh active
- 2013-05-22 WO PCT/EP2013/060534 patent/WO2013174876A1/en active Application Filing
- 2013-05-22 MX MX2014013924A patent/MX355409B/es active IP Right Grant
- 2013-05-22 EP EP19188774.4A patent/EP3581571A1/en not_active Withdrawn
- 2013-05-22 NZ NZ716487A patent/NZ716487A/en unknown
- 2013-05-22 PL PL17195806T patent/PL3333166T3/pl unknown
- 2013-05-22 CN CN201380026532.6A patent/CN104395308B/zh active Active
- 2013-05-22 EP EP13724270.7A patent/EP2855460B1/en not_active Withdrawn - After Issue
- 2013-05-22 CN CN201610455414.2A patent/CN106167485A/zh active Pending
- 2013-05-22 KR KR1020147036163A patent/KR102151963B1/ko active IP Right Grant
- 2013-05-22 EP EP17195806.9A patent/EP3333166B1/en active Active
- 2013-05-22 ES ES17195806T patent/ES2771100T3/es active Active
- 2013-05-22 PL PL17192138T patent/PL3290414T3/pl unknown
- 2013-05-22 CA CA2873979A patent/CA2873979C/en active Active
- 2013-05-22 AU AU2013265288A patent/AU2013265288B2/en active Active
- 2013-05-22 NZ NZ703124A patent/NZ703124A/en unknown
- 2013-05-22 EP EP17192138.0A patent/EP3290414B1/en active Active
- 2013-05-23 AR ARP130101795 patent/AR091138A1/es unknown
-
2014
- 2014-10-30 US US14/528,475 patent/US9085565B2/en active Active
- 2014-11-18 IL IL235761A patent/IL235761B/en active IP Right Grant
-
2015
- 2015-05-20 US US14/716,986 patent/US9382235B2/en active Active
- 2015-08-11 HK HK15107770.4A patent/HK1207077A1/zh unknown
-
2016
- 2016-06-03 US US15/172,478 patent/US9649306B2/en active Active
-
2018
- 2018-02-13 AU AU2018201037A patent/AU2018201037B2/en active Active
- 2018-06-27 IL IL260297A patent/IL260297A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
HK1259405A1 (zh) | N-[5-(3,5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氫吡喃-4-基氨基)-苯甲酰胺的新晶型 | |
HK1217487A1 (zh) | 用於治療成癮的作為乙醛脫氫酶- 抑制劑的 -氧基- -二氫-吡啶- -基 -芐基 -苯甲酰胺衍生物 | |
HK1200827A1 (zh) | 用於生產 -二甲基-苯基硫烷基 -苯基 -哌嗪的方法 | |
IL232462A (en) | Annals of 2- (1, 2, 3-triazole-2-ram) benzamide and 3- (3,2,1-triazole-2-ram) picolinamide, containing and using pharmaceutical preparations | |
HK1214822A1 (zh) | 新型 苄氧基 苯基 己- -炔酸衍生物、其製備方法、和包括其作為有效成分的用於預防和治療代謝性疾病的藥物組合物 | |
IL237378B (en) | Derivatives of 1-(phenyl/pyrid-4-yl)-3-(phenyl-oxazolyl-5-(methyl-4,2,1,-triazole) and pharmaceutical compounds containing them | |
ZA201402907B (en) | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | |
IL233937A (en) | Process for making phenyl-3-diphloromethyl-1-methyl-1h-pyrazole-4-carboxylic-n-methoxy-[1-methyl-2-phenylethyl] amide | |
PL2901857T3 (pl) | Sposób wytwarzania 3-chloro-4,5,6-trifluoro-pikolinonitrylu | |
SI2532651T1 (sl) | Postopek sinteze in kristalinična oblika 4-(3-(cis-heksahidrociklopenta(c)pirol-2(1H)-il)propoksi) benzamid hidroklorida ter njegova prosta baza, pa tudi farmacevtski sestavki, ki ju vsebujejo | |
SI2608789T1 (sl) | Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina | |
HUP1100351A2 (en) | Process for the preparation of (5alpha,17beta)-n-[2,5-bis-(trifluoromethyl)-phenyl]-3-oxo-4-aza-5-androst-1-en-17-carboxylic amide | |
HK1212229A1 (zh) | -二甲氧基苯基 乙基 -吡唑- -基 -二甲基哌嗪- -基 苯甲酰胺的醫藥配製品 | |
HK1193612A1 (zh) | 用於製備 -甲基- -四氫- -苯並吖庚因- -基羰基 苄基氨基甲醯基- -脯氨酸- -二甲基醯胺的方法 | |
IL238829A0 (en) | Process for the preparation of 4-(cyclopropylmethoxy-3,5)-n-(dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide | |
HUE043092T2 (hu) | Eljárás l-[2-(2,4-dimetil-fenilszulfanil)-fenil]-piperazin elõállítására | |
MX2016010549A (es) | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas. | |
PL399182A1 (pl) | Sposób wytwarzania nilotinibu | |
IN2013MU01336A (zh) | ||
PL392035A1 (pl) | Nowe pochodne 3-[(imidazolidyn-2-ylo) imino]indazolu, sposób ich otrzymywania oraz zastosowanie farmaceutyczne |